Related Experiment Video
Updated: Aug 30, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.3K
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study
Maddalena Napolitano1, Gabriella Fabbrocini2, Iria Neri3
1Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy. maddy.napolitano@gmail.com.
Paediatric Drugs
|August 26, 2022
Summary
Dupilumab effectively treats moderate-to-severe paediatric atopic dermatitis (AD) in children aged 6-11 years. Real-world data show significant improvements in skin severity, itch, sleep, and quality of life with a favorable safety profile.
Area of Science:
- Dermatology
- Paediatric Medicine
- Immunology
Background:
- Paediatric atopic dermatitis (AD) management is challenging, often relying on topical treatments.
- Dupilumab, a monoclonal antibody, is approved for moderate-to-severe AD in children aged 6-11 years unresponsive to topical therapies.
Purpose of the Study:
- To evaluate the real-life effectiveness and safety of dupilumab in treating children aged 6-11 years with moderate-to-severe AD.
Main Methods:
- Retrospective data collection from 24 centers on 55 children (aged 6-11) with moderate-to-severe AD treated with dupilumab.
- Dupilumab administered subcutaneously: 300 mg induction, then 300 mg every 4 weeks.
- Efficacy assessed using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS), Sleep NRS (S-NRS), and Children's Dermatology Life Quality Index (c-DLQI) at baseline and weeks 2, 4, and 16.
Main Results:
- Significant improvements observed in EASI, P-NRS, S-NRS, and c-DLQI from baseline to week 16.
- At week 16, 74.54% of patients achieved EASI75.
- Significant mean percentage reductions at week 16: P-NRS (68.39%), S-NRS (70.22%), and c-DLQI (79.03%).
Conclusions:
- Real-world data support dupilumab's effectiveness in paediatric AD across all disease aspects.
- Dupilumab improved disease severity, symptom intensity, sleep, and quality of life.
- The treatment demonstrated a good safety profile in this paediatric population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
257
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
257
01:19Antiasthma Drugs: Leukotriene Modifiers
428
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
428
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
217
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
217
01:30Skin Cancer
4.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.4K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
413
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
413
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
194
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
194